Humacyte Inc SEC Filings

Brady W. Dougan, a director of Humacyte, Inc. (HUMA), reported sales of common stock executed by Ayabudge LLC, an entity he controls. Between 08/18/2025 and 08/20/2025 Ayabudge sold a total of 2,241,045 shares in multiple transactions at weighted average prices of $1.83, $1.63 and $1.58 per share (per-footnote ranges: $1.79–$1.92, $1.57–$1.76, $1.53–$1.69). After the reported transactions Ayabudge beneficially owned 0 shares. The filing shows Mr. Dougan retains indirect beneficial ownership of 243,851 shares through his spouse and 1,148,240 shares through The Niklason Living Trust.

Laura E. Niklason, President, CEO and Director of Humacyte, Inc. (HUMA), reported changes in beneficial ownership on Form 4 related to sales of common stock held indirectly by Ayabudge LLC, an entity controlled by Brady W. Dougan. The filing discloses three groups of sales: 549,360 shares on 08/18/2025 at a weighted average price of $1.83, 1,100,000 shares on 08/19/2025 at a weighted average price of $1.63, and 591,685 shares on 08/20/2025 at a weighted average price of $1.58. Following the reported transactions, Ayabudge LLC's indirect holdings of those shares were reduced to zero. The filing also shows direct ownership of 243,851 shares and indirect ownership of 1,148,240 shares held by The Niklason Living Trust. The explanatory notes state the sales were executed by Ayabudge LLC to allow Mr. Dougan to pay down leverage and to provide a mechanism for investors to acquire shares; Dr. Niklason did not directly sell any shares. The Form 4 is signed on behalf of Dr. Niklason by an attorney-in-fact.

Humacyte, Inc. (HUMA) Form 144 reports a proposed sale of 591,685 common shares valued at $936,653.92 to be sold approximately on 08/20/2025 through UBS Financial Services on NASDAQ. The filer states the shares were originally acquired on 08/26/2021 as an early-stage investor position converted to Humacyte shares upon the company’s SPAC transaction; the original block purchased was 18,930,004 shares and payment was in cash. The filing also discloses recent dispositions by AYABUDGE LLC of 549,360 shares on 08/18/2025 (gross proceeds $997,429) and 1,100,000 shares on 08/19/2025 (gross proceeds $1,790,244). The filer certifies no undisclosed material adverse information.

Humacyte, Inc. notice of proposed sale reports an intended sale of 1,100,000 common shares through UBS Financial Services on or about 08/19/2025 on NASDAQ, with an aggregate market value of $1,790,244.50. The filing shows the shares were originally acquired on 08/26/2021 as early-stage investor holdings converted to Humacyte shares when the company went public via a SPAC, and payment for the original acquisition was in cash. The filer also reported sales during the prior three months: 549,360 shares sold on 08/18/2025 for gross proceeds of $997,429. The filing includes the filers representation that no undisclosed material adverse information is known.

Form 144 notice for HUMA (Humacyte, Inc.) reporting a proposed sale of common stock. The filer plans to sell 549,360 shares through UBS Financial Services Inc. on or about 08/18/2025, with an aggregate market value of $1,002,928.10. The company has 158,372,173 shares outstanding. The securities were originally acquired on 08/26/2021 as an early-stage investment in AHAC and converted to Humacyte shares when the company went public via SPAC; the original acquired amount shown is 18,930,004 shares with payment listed as cash. No securities were reported sold in the past three months. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.

Humacyte reported early commercial activity for Symvess and maintained meaningful liquidity while continuing R&D spending. Cash and cash equivalents were $38.0 million with restricted cash of $50.2 million, totaling $88.4 million of cash and restricted cash. Total assets were $138.8 million and stockholders' equity was $4.1 million. The company recognized product and contract revenue of $0.3 million in Q2 2025 and $0.8 million for the six months ended June 30, 2025, and capitalized $11.1 million of inventory related to Symvess.

Operating expenses remained high: R&D was $37.4 million for six months and the operating loss was $52.9 million for the same period. Net results for the six months show a $1.5 million net income driven largely by a $44.3 million favorable change in the fair value of a contingent earnout liability, while the three‑month period posted a $37.7 million net loss. Financing activity included a $46.7 million public offering (net) and ATM proceeds of $3.6 million in the first half of 2025. The company implemented workforce reductions and expects existing cash plus available equity commitments to fund operations for at least twelve months from these interim statements.

Humacyte, Inc. furnished a press release reporting its financial results for the fiscal second quarter ended June 30, 2025. The press release is attached as Exhibit 99.1 and is incorporated by reference into this Current Report, but the body of the Form 8-K does not include the underlying financial figures or tables.

The filing explicitly states that the information, including the exhibit, "shall not be deemed filed" for purposes of Section 18 of the Exchange Act and will not be incorporated by reference in other filings except by specific reference. The report also identifies the company as an emerging growth company and lists its securities as Common Stock (HUMA) and Redeemable Warrants (HUMAW) on Nasdaq. The filing includes Exhibit 99.1 and the Cover Page Interactive Data File (Exhibit 104).